title: Resibufogenin prevents the manifestations of preeclampsia in an animal model of the syndrome.
abstract: OBJECTIVE
  We have developed a rat model of preeclampsia which is based upon excessive volume expansion and includes hypertension, proteinuria and intrauterine growth restriction. In this model, the urinary excretion of the circulating steroid inhibitor of Na +/ K+ ATPase, marinobufagenin, is increased prior to the development of hypertension and proteinuria. An analogue of marinobufagenin, resibufogenin, successfully treats the hypertension and proteinuria.
  
  
  METHODS
  We administered resibufogenin early in pregnancy in this model, prior to the development of the syndrome.
  
  
  RESULTS
  We found that resibufogenin not only prevented the advent of hypertension and proteinuria, but also the development of intrauterine growth restriction.
  
  
  CONCLUSIONS
  These results may have relevance to the human condition.
authors.affiliation: Department of Medicine, Texas A & M College of Medicine/Scott & White, Temple, USA.
authors.forename: Darijana
authors.initials: D
authors.lastname: Horvat
authors.forename: Jud
authors.initials: J
authors.lastname: Severson
authors.forename: Mohammad N
authors.initials: MN
authors.lastname: Uddin
authors.forename: Brett
authors.initials: B
authors.lastname: Mitchell
authors.forename: Jules B
authors.initials: JB
authors.lastname: Puschett
mesh_terms: D000818:Animals; D002018:Bufanolides / Q000627:therapeutic use*; D004195:Disease Models, Animal; D005260:Female; D005317:Fetal Growth Retardation / Q000188:drug therapy / Q000517:prevention & control*; D006973:Hypertension / Q000188:drug therapy / Q000517:prevention & control*; D011225:Pre-Eclampsia / Q000188:drug therapy* / Q000517:prevention & control*; D011247:Pregnancy; D011507:Proteinuria / Q000188:drug therapy / Q000517:prevention & control*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D002018:Bufanolides; C005734:bufogenin